Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DB25FW3V8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,358
Award facts
- Contract value 100% obligated
- $17,357.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
On September 9, 2025, the Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $17,357.75 to DMS Pharmaceutical Group Inc. for the supply of Nexplanon 68 mg implants. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this contract through its Park Ridge facility with an ultimate completion date of September 30, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete on an unrestricted basis. The award represents a discrete order under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA, valued at approximately $500 million and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies to support Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, holding a single-award IDC under the SPE2DB program that covers an extensive portfolio of branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. The company's contract awards demonstrate consistent success in delivering specialized pharmaceutical products, including contraceptive devices, oncology treatments, vaccines, and auto-injectors to military health facilities. As a registered woman-owned small business in the System for Award Management (SAM.gov) since 2001, DMS Pharmaceutical Group leverages its small business status to compete effectively in federal procurement markets while maintaining a robust track record of pharmaceutical product delivery to the Defense Logistics Agency.
Quick answers
Who was awarded contract SPE2DB25FW3V8?
SPE2DB25FW3V8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 9, 2025.
How much is contract SPE2DB25FW3V8 worth?
The government has obligated $17,358 on SPE2DB25FW3V8.
Is contract SPE2DB25FW3V8 an order under another contract?
Yes. SPE2DB25FW3V8 is a delivery order under SPE2DB20D9335, an indefinite delivery contract.
Was contract SPE2DB25FW3V8 competed?
The extent of competition for SPE2DB25FW3V8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award